Bicara Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesChemicals & Related Products · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
116 Huntington Ave Ste 703, Boston, Mass...Phone Number
(617) 468-4219Website
www.bicara.comRevenue
-Stock Symbol
BCAXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Bicara Therapeutics
Bicara Therapeutics is focused on combating cancer by merging targeted therapies with tumor-microenvironment modulators to develop more effective medicines for patients. The company aims to improve treatment options for individuals affected by cancer. Their innovative approach leverages scientific advancements to address the complexities of tumor biology. Bicara Therapeutics is dedicated to transforming the landscape of cancer treatment.Explore more
Bicara Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bicara Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Bicara Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Bicara Therapeutics is spiking on competitors!
Bicara Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Bicara Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Bicara Therapeutics
Check if Bicara Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Bicara Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Bicara Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Bicara Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Bicara Therapeutics
Compare insights from companies similar to Bicara Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Bicara Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Bicara Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Bicara Therapeutics.
Bicara Therapeutics financials insights
Gather financial insights about Bicara Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series B
$108M
Series C
$165M
2024
Stock Offering
$315M
Bicara Therapeutics Tech Stack
A closer look at the technologies used by Bicara Therapeutics
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Earnings, Finance
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Project
Clinical Operations
Bicara Therapeutics News & Media
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective August 12, 2026, it awarded an inducement grant to Jennifer Larson under Bicara’s 2026 Inducement Plan as a material inducement to her commencement of employment as Bicara’s Chief Financial Officer.Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary
Moby summary of Bicara Therapeutics Inc. Common Stock's Q2 2026 earnings callBicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call August 11, 2026 8:30 AM EDTCompany ParticipantsRachel Frank - Vice President of Investor Relations and...Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth
President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bicara Therapeutics
Sign Up For FreeTo access detailed company insights
Bicara Therapeutics is focused on combating cancer by merging targeted therapies with tumor-microenvironment modulators to develop more effective medicines for patients. The company aims to improve treatment options for individuals affected by cancer. Their innovative approach leverages scientific advancements to address the complexities of tumor b... Read More
